Oncopeptides AB Statistics

Total Valuation

Oncopeptides AB has a market cap or net worth of SEK 1.46 billion. The enterprise value is 1.46 billion.

Market Cap	1.46B
Enterprise Value	1.46B

Important Dates

The next estimated earnings date is Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Oncopeptides AB has 272.71 million shares outstanding. The number of shares has increased by 58.45% in one year.

Current Share Class	258.57M
Shares Outstanding	272.71M
Shares Change (YoY)	+58.45%
Shares Change (QoQ)	+7.65%
Owned by Insiders (%)	0.70%
Owned by Institutions (%)	16.61%
Float	229.35M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	23.36
PB Ratio	223.15
P/TBV Ratio	223.15
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-5.45
EV / Sales	23.37
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-6.39

Financial Position

The company has a current ratio of 3.42, with a Debt / Equity ratio of 22.75.

Current Ratio	3.42
Quick Ratio	3.27
Debt / Equity	22.75
Debt / EBITDA	n/a
Debt / FCF	-0.65
Interest Coverage	-7.60

Financial Efficiency

Return on equity (ROE) is -376.73% and return on invested capital (ROIC) is -75.21%.

Return on Equity (ROE)	-376.73%
Return on Assets (ROA)	-57.86%
Return on Invested Capital (ROIC)	-75.21%
Return on Capital Employed (ROCE)	-158.10%
Revenue Per Employee	832,867
Profits Per Employee	-3.57M
Employee Count	80
Asset Turnover	0.24
Inventory Turnover	0.20

Taxes

In the past 12 months, Oncopeptides AB has paid 1.02 million in taxes.

Income Tax	1.02M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +245.61% in the last 52 weeks. The beta is -1.42, so Oncopeptides AB's price volatility has been lower than the market average.

Beta (5Y)	-1.42
52-Week Price Change	+245.61%
50-Day Moving Average	5.33
200-Day Moving Average	3.49
Relative Strength Index (RSI)	51.27
Average Volume (20 Days)	1,751,968

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oncopeptides AB had revenue of SEK 62.47 million and -267.84 million in losses. Loss per share was -1.24.

Revenue	62.47M
Gross Profit	61.14M
Operating Income	-245.55M
Pretax Income	-266.82M
Net Income	-267.84M
EBITDA	-243.05M
EBIT	-245.55M
Loss Per Share	-1.24

Full Income Statement

Balance Sheet

The company has 147.92 million in cash and 148.77 million in debt, giving a net cash position of -851,000 or -0.00 per share.

Cash & Cash Equivalents	147.92M
Total Debt	148.77M
Net Cash	-851,000
Net Cash Per Share	-0.00
Equity (Book Value)	6.54M
Book Value Per Share	0.02
Working Capital	135.39M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -227.93 million and capital expenditures -357,000, giving a free cash flow of -228.28 million.

Operating Cash Flow	-227.93M
Capital Expenditures	-357,000
Free Cash Flow	-228.28M
FCF Per Share	-0.84

Full Cash Flow Statement

Margins

Gross Margin	97.88%
Operating Margin	-393.09%
Pretax Margin	-427.15%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Oncopeptides AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-58.45%
Shareholder Yield	-58.45%
Earnings Yield	-18.36%
FCF Yield	-15.65%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3